Peiling Yang, PhD

Consensus Statement

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

August 26, 2015

Ni A. Khin, Phillip D. Kronstein, Peiling Yang, et al

Review Article

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

August 26, 2015

Phillip D. Kronstein, Eiji Ishida, Ni A. Khin, et al

Perspective

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

November 11, 2014

Jing Zhang, Mitchell V. Mathis, Jenn W. Sellers, et al

Review Article

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

March 15, 2014

Silvana Borges, Yeh-Fong Chen, Thomas P. Laughren, et al

Review Article

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

May 15, 2012

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

Letter to the Editor

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

September 15, 2011

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

Original Research

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

September 15, 2011

Thomas P. Laughren, Jogarao Gobburu, Robert J. Temple, et al

Original Research

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

April 15, 2011

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

ELSEWHERE:

FOLLOW US:

Peiling Yang, PhD

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles